Celcuity's breast cancer win; Odyssey plans $205M IPO
Celcuity’s breast cancer drug wins again: The company said two regimens with its experimental drug gedatolisib succeeded in PIK3CA mutant patients as part of its Phase 3 trial. Last year ...
May 4, 2026 10:54 AM EDT News Briefing Celcuity breast cancer win; Odyssey plans $205M IPO; Latus Bio extends Series A ENDPOINTS Celcuity’s breast cancer drug wins again: The company said two regimens with its experimental drug gedatolisib succeeded in PIK3CA mutant … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that